The Patient Experience Behind the Numbers

The JAMA Network Open study makes the pharmacy gate visible from the patient's side. It asks how often adults receiving telemedicine treatment for opioid use disorder encountered problems filling buprenorphine, how long those problems left them without medication, and whether rural residence explained the difference. Reading the results carefully gives a more useful judgment than a single prevalence figure: the survey shows that interruptions were common in this sample, while also showing why the findings cannot be treated as a national rate or a causal ranking of places.

The study matters because the CDC map measures annual retail dispensing activity, while a patient experiences access as a series of deadlines. A prescription must be filled before the current supply runs out. If a pharmacy needs to order the medication, an insurer delays payment, or a telemedicine prescription is questioned, the annual record may not reveal the time lost. The survey connects those mechanisms to reported treatment interruptions, but it does so within a defined population and study design.

What 601 telemedicine patients reported

From August through September 2024, the researchers conducted a cross-sectional web-based survey of adults receiving low-barrier telemedicine treatment for opioid use disorder at one multistate practice. The five states were Florida, Michigan, New Jersey, Ohio, and Texas. Patients were eligible if they were at least 18 years old, had a clinical diagnosis of OUD, had completed an initial evaluation and a follow-up appointment, and had a valid ZIP code in their records. Of 1,800 invited patients, 601 participated, a response rate of 33.4%.

The design was intentionally structured to compare rural and nonrural experiences. The researchers used ZIP codes mapped to Rural-Urban Commuting Area codes and sampled in strata so that the groups would be represented in roughly equal numbers. In the final sample, 301 participants, or 50.1%, lived in areas classified as rural and 300, or 49.9%, lived in nonrural areas. The survey measured self-reported problems filling buprenorphine in the past year, the types of problems, whether those problems were resolved, the number of days without medication, and interest in having medication shipped.

That description establishes what the percentages mean. They are not the share of all U.S. patients, all telemedicine patients, or all pharmacy customers. They are the share of 601 adults in one practice who completed the survey and answered questions about their past-year experience. The study is still informative because it observes a patient-level outcome that an annual dispensing map cannot. But its value is strongest when the reader keeps the denominator and setting in view.

The headline result was that 192 participants, or 31.9%, reported that they had gone without buprenorphine during the previous 12 months because they could not get a prescription filled at a pharmacy. This is a direct continuity signal: it does not merely say that a fill was inconvenient. It says that a pharmacy-related problem left the person without medication for at least some period.

A related measure found that 165 participants, or 27.5% of the full sample, reported a problem filling their buprenorphine prescription during the previous year.